[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cabg-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cabg-patients":136},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,71,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100629209","phase-1-hipsc-cms-loaded-chitosan-patch-to-treat-severe-chronic-ischemic-heart-disease-100629209",false,"NCT07471698","hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Induce Pluripotent Stem Cell-derived Cardiomyocytes(HiCM-188) -Loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease","Inclusion Criteria:\n\n1. Age between 18 and 80 years (inclusive).\n2. Willingness and ability to give written informed consent.\n3. Chronic left ventricular dysfunction classified as Stage D (refractory end-stage heart failure) according to ACC staging criteria.\n4. NYHA functional class III-IV despite optimized guideline-directed medical therapy for heart failure.\n5. Indication for coronary artery bypass grafting (CABG), meeting one of the following anatomical criteria:\n\n   5.1 Class I Indications :\n   1. Left ventricular dysfunction with significant left main coronary artery disease;\n   2. Left ventricular dysfunction with \"left main equivalent\" disease (i.e., ≥70% stenosis in proximal LAD or proximal LCx);\n   3. Left ventricular dysfunction with two- or three-vessel disease including proximal LAD stenosis.\n\n   5.2 Class IIa Indication : Left ventricular dysfunction with substantial viable, akinetic but revascularizable myocardium, not covered by above Class I anatomical criteria.\n6. Left ventricular ejection fraction (LVEF) ≤40% as measured by echocardiography or cardiac MRI within 6 months prior to enrollment (excluding measurements obtained within 1 month post-myocardial infarction).\n7. Echocardiographic evidence of regional wall motion abnormalities (hypokinesis, akinesis, or presence of ventricular aneurysm).\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria are ineligible for study participation:\n\n1. History of permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device implantation.\n2. Severe valvular heart disease or prior prosthetic valve replacement.\n3. Prior percutaneous coronary intervention (PCI) with stent implantation.\n4. Chronic atrial fibrillation.\n5. History of sustained ventricular tachycardia or aborted sudden cardiac death.\n6. Baseline estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m².\n7. Hematocrit \\\u003C25%.\n8. Severe contrast media allergy (anaphylactic or life-threatening reaction history).\n9. Coagulation disorder (INR \\>1.5 without therapeutic anticoagulation, platelets \\\u003C50×10⁹\u002FL, or clinically significant bleeding diathesis).\n10. Known hypersensitivity to penicillin or streptomycin.\n11. Contraindication to undergoing cardiac MRI (e.g., incompatible implanted devices, severe claustrophobia unresponsive to premedication).\n12. History of solid organ or bone marrow transplantation.\n13. Active malignancy or history of cancer within the past 5 years (except non-melanoma skin cancer or carcinoma in situ).\n14. Life expectancy \\\u003C1 year due to non-cardiac conditions.\n15. Long-term systemic immunosuppressive therapy (e.g., corticosteroids, TNF-α inhibitors).\n16. Contraindications to immunosuppressive therapy (e.g., active infection, uncontrolled diabetes, peptic ulcer disease).\n17. Active infectious diseases: HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis (Treponema pallidum, TP).\n18. Currently participating in another interventional clinical trial.\n19. Pregnant or lactating women.","ALL","18 Years","80 Years",{"count":20,"type":21},16,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is an exploratory study. A total of 16 patients meeting the inclusion and exclusion criteria and awaiting coronary artery bypass grafting (CABG) surgery will be enrolled. After providing informed consent, participants will be randomized 1:1 under double-blind conditions into two groups:\n\n1. CABG + HiCM-188-loaded chitosan patch group (patch size: 2×4 cm; containing 5 million cells per patch)\n2. CABG + blank chitosan patch group (identical in appearance but without HiCM-188 cells).\n\nDuring CABG surgery, investigators will apply two HiCM-188-loaded chitosan patches onto the epicardial surface over regions of hypokinetic myocardium. The total transplanted cell dose per patient in the treatment group is 1 × 10⁷ . In the control group, eight patients will undergo identical surgical procedures with application of chitosan patches without HiCM-188 cells.",[28,29],"Ischemic Heart Failure","CABG-patients","NOT_YET_RECRUITING","2026-03-10",{"date":33,"type":34},"2026-03-13","ACTUAL",{"date":36,"type":21},"2026-10-20",{"date":38,"type":21},"2028-10-20",{"name":40,"class":41},"HELP Therapeutics Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100572879","ai-model-for-assessing-cardiac-surgeons-techniques-100572879","NCT06739005","AI Model for Assessing Cardiac Surgeons' Techniques","artifiCiAl Intelligence Model for Evaluating the Surgical Techniques of caRdiAc Surgeons (CAMERA)","CAMERA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing internal mammary artery-to-left anterior descending artery bypass grafting\n* First-time recipient of isolated CABG surgery\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Patients with acute coronary syndrome\n* Patients with contraindications to coronary CT angiography or coronary angiography\n* Patients with renal insufficiency or active liver disease, including those with persistently elevated serum transaminases of unknown cause or any serum transaminase levels exceeding three times the upper limit of normal.",{"count":52,"type":21},284,"OBSERVATIONAL","The goal of this study aims to investigate the use of artificial intelligence to analyze and evaluate the characteristics and proficiency of surgeons during vascular anastomosis in coronary artery bypass grafting (CABG) procedures. The main question it aims to answer is:\n\nConsistency assessment between AI evaluation scores and human expert evaluation scores for surgeons during left anterior descending (LAD) artery anastomosis.",[29,56,57,58,59],"CABG","Cardiovascular Surgery","Surgeons","Artificial Intelligence (AI)","RECRUITING","2025-09-19",{"date":63,"type":34},"2025-09-23",{"date":65,"type":34},"2025-01-09",{"date":67,"type":21},"2027-07",{"name":69,"class":70},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":92,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":42},"100593147","clinical-impact-of-surgical-wound-morbidity-according-to-the-type-of-saphenous-vein-harvesting-technique-endoscopic-vs-open-in-patients-undergoing-myocardial-revascularization-surgery-100593147","NCT07002658","Clinical Impact of Surgical Wound Morbidity According to the Type of Saphenous Vein Harvesting Technique (Endoscopic vs. Open) in Patients Undergoing Myocardial Revascularization Surgery","Endoscopic Saphenous Vein Harvesting Versus Conventional Open Harvesting in Patients Undergoing Coronary Artery Bypass Grafting, Either Alone or in Combination With Another Cardiac Surgical Procedure, in Terms of the Clinical Impact of Surgical Wound Morbidity","EndOSiC","Inclusion Criteria:\n\n* Patients undergoing coronary artery bypass grafting (CABG), alone or in combination with other surgery (valve or arrhythmia surgery), with or without cardiopulmonary bypass (CPB), in which preoperative evaluation includes the plan to use a short saphenous vein segment (alone or in addition to arterial conduits).\n* Availability of a surgeon or cardiac surgery resident trained in endoscopic harvesting in the operating room.\n* Patients undergoing myocardial revascularization surgeries with or without extracorporeal circulation.\n* Patients undergoing concomitant cardiac valve replacement surgery, atrial fibrillation surgery, and others, in addition to CABG\n\nExclusion Criteria:\n\n* Emergent surgery or procedures performed during cardiorespiratory arrest\n* Myocardial revascularization with arterial grafts only\n* Presence of varicose veins\n* History of infrainguinal vascular surgery\n* Presence of ulcers and\u002For active infection in the lower limbs\n* Previous stroke with neurological sequelae in the legs\n* History of deep vein thrombosis in the legs\n* Pregnancy\n* Age under 18 years\n* Lack of signed informed consent",{"count":80,"type":21},356,[82],"NA","The goal of this clinical trial is to compare two different techniques: endoscopic saphenous vein harvesting versus conventional open harvesting in patients undergoing coronary artery bypass grafting, either alone or in combination with another cardiac surgical procedure (valve surgery or arrhythmia surgery). The main questions the trial aims to answer are:\n\nDoes the endoscopic technique reduce surgical wound morbidity in terms of shorter hospital stays? Does endoscopic saphenous harvesting reduce the use of antibiotics for saphenectomy wound infections? Does the endoscopic technique reduce need for wound dressings due to necrosis and\u002For wound infection, and reduce need for analgesic treatment for wound pain? This prospective, randomized study will be conducted in the Cardiovascular Surgery Service at Hospital Clínico San Carlos.\n\nParticipants will be randomly assigned to a different saphenectomy technique. All patients will be assessed for saphenectomy wound complications upon discharge, and by phone call at 7 days, 1 month, and 3 months following the intervention.",[29,85,86,87,88,89,90,91],"Saphenectomy","Endoscopic Surgery","Wound Complications","Antibiotic Use","Cardiac Surgery","Off Pump Coronary Artery Bypass Graft","Coronary Artery Bypass Graft With or Without ECC",[93,94,95,96],"endoscopic vein harvesting","CABG surgery","open vein harvesting","wound morbidity","2025-06-03",{"date":99,"type":34},"2025-06-06",{"date":101,"type":21},"2025-07-01",{"date":103,"type":21},"2026-08-01",{"name":105,"class":106},"Hospital San Carlos, Madrid","OTHER",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":42},"100589622","phase-1-safety-and-efficacy-of-epicardial-implantation-of-collagen-membranes-with-allogeneic-adipose-derived-stem-cells-100589622","NCT06956807","Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells","First in Human Open Label Multicentre Clinical Trial to Evaluate the Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells in Patients With Ischaemic Left Ventricular Dysfunction Scheduled to Undergo Coronary Revascularisation Surgery","CARDIOMESH II","Inclusion Criteria:\n\n1. Patients planning to undergo coronary revascularisation surgery within one month of study entry.\n2. LVEF ≤45% by CMRI.\n3. History of myocardial infarction at least 3 months prior to inclusion.\n4. Scar covering at least 15% of the total left ventricular myocardial mass defined by late enhancement on CMRI.\n\nExclusion Criteria:\n\n1. Participation in another clinical trial within 30 days prior to inclusion.\n2. Prior treatment with cell or gene therapy.\n3. Be a candidate for heart transplant at the time of study entry.\n4. Diagnosis of acute myocardial infarction with 3 months prior to inclusion.\n5. Need for urgent revascularisation surgery.\n6. Strict contraindication for the use of CMRI (pacemaker or implantable automatic defibrillator carriers, previous reactions to gadolinium contrast, claustrophobia, cochlear implants, etc.).\n7. Presence of uncontrolled ventricular arrhythmias (ventricular tachycardia or ventricular fibrillation) at the time of implant surgery.\n8. Active systemic infection.\n9. Women who are pregnant or breastfeeding.\n10. Mental disease or psychological condition that impedes the subject from understanding the nature of the protocol and granting his\u002Fher consent\n11. Advanced dementia according to the Barthel index.\n12. History of primary or acquired immunodeficiency or on immunosuppressive therapy (within 3 months prior to inclusion or if the need for immunotherapy is foreseeable at any time during the study follow up).\n13. Tumour disease, except that eradicated at least 5 years prior to inclusion in the study and without receiving chest radiotherapy. Completely eradicated non melanoma skin tumours (at any time) not requiring chest chemotherapy or radiotherapy are permitted.\n14. History of autoimmune disease.\n15. Stroke within 12 months prior to inclusion.\n16. Respiratory compromise or need for home oxygen therapy.\n17. Life expectancy of less than 1 year for any reason",{"count":116,"type":21},10,[24],"* The Cardiomesh II clinical trial is a phase I open label study intended to enrol 10 patients to evaluate the safety and efficacy of surgical epicardial implantation of a membrane seeded with allogeneic adipose tissue derived stem cells in patients scheduled to undergo coronary revascularisation surgery and at high risk of developing heart failure.\n* The primary objective of the study is to evaluate the safety of surgical implantation of this membrane in patients with large ischaemic myocardial scars scheduled to undergo coronary revascularisation surgery. The secondary objective is to investigate the efficacy of the above treatment in terms of reduction of scar size and ventricular function parameters.",[29,120,121],"Heart Failure","Myocardial Infarction (MI)",[123,124,125,126],"heart failure","coronary revascularisation surgery","adipose-derived stem cells","myocardial infarction","2025-04-24",{"date":129,"type":34},"2025-05-04",{"date":131,"type":21},"2025-09-01",{"date":133,"type":21},"2027-06-30",{"name":135,"class":41},"Viscofan","CABG-Patients"]